OncoHost presented a poster at the European Society of Medical Oncology (ESMO) Congress 2024 demonstrating the potential of its PROphet platform in predicting clinical outcomes for renal cell carcinoma (RCC). The study, a collaboration with Dana-Farber Cancer Institute, suggests the platform, initially developed for non-small cell lung cancer (NSCLC), can effectively risk stratify RCC patients.
The research involved a cohort of 201 RCC patients treated with VEGFR tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or a combination of both. Patients identified as PROphet-POSITIVE exhibited significantly improved overall survival (OS) and progression-free survival (PFS) compared to those classified as PROphet-NEGATIVE. These findings indicate the platform's potential to predict clinical outcomes across various cancer types and treatment modalities.
Proteomic Analysis Reveals Treatment-Specific Signatures
The study also uncovered distinct subsets of circulating proteins associated with clinical benefit among patients treated with different therapies. This suggests that the proteomic features leveraged by the PROphet platform may have broad predictive value, potentially guiding treatment decisions based on individual patient profiles.
Dr. Eddy Saad, MD, MSc, a Postdoctoral Research Fellow at Dana-Farber and co-author of the abstract, stated, "In this work, we demonstrated that OncoHost's plasma-based proteomic model, initially trained and validated in NSCLC, can also be applied to another tumor type, RCC, to risk stratify patients. Moving forward, we aim to further develop and train an RCC-specific model and assess its predictive abilities to guide patient treatment."
Future Directions and Clinical Implications
Ofer Sharon, MD, CEO of OncoHost, emphasized the significance of these findings: "This research marks another important milestone for OncoHost, as it demonstrates the versatility and potential of our PROphet platform across different cancer types. By validating the use of our proteomic model in renal cell carcinoma, we are moving closer to our goal of providing personalized treatment plans that significantly improve patient outcomes."
The company plans to further develop and refine an RCC-specific model to enhance its predictive capabilities and guide patient treatment strategies. This expansion of the PROphet platform aims to provide clinicians with valuable insights for personalized treatment decisions in RCC and potentially other cancer types.
